165 related articles for article (PubMed ID: 27598317)
1. Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study.
Brancaccio D; Neri L; Bellocchio F; Barbieri C; Amato C; Mari F; Canaud B; Stuard S
Am J Nephrol; 2016; 44(4):258-267. PubMed ID: 27598317
[TBL] [Abstract][Full Text] [Related]
2. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
Van Der Meersch H; De Bacquer D; De Vriese AS
Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.
Winkelmayer WC; Liu J; Setoguchi S; Choudhry NK
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2662-8. PubMed ID: 21959598
[TBL] [Abstract][Full Text] [Related]
4. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation.
Kai B; Bogorad Y; Nguyen LN; Yang SJ; Chen W; Spencer HT; Shen AY; Lee MS
Heart Rhythm; 2017 May; 14(5):645-651. PubMed ID: 28185918
[TBL] [Abstract][Full Text] [Related]
5. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.
Shen JI; Montez-Rath ME; Lenihan CR; Turakhia MP; Chang TI; Winkelmayer WC
Am J Kidney Dis; 2015 Oct; 66(4):677-88. PubMed ID: 26162653
[TBL] [Abstract][Full Text] [Related]
6. Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Nationwide Population-Based Study.
Yoon CY; Noh J; Jhee JH; Chang TI; Kang EW; Kee YK; Kim H; Park S; Yun HR; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Kim C; Yoo TH
Stroke; 2017 Sep; 48(9):2472-2479. PubMed ID: 28801476
[TBL] [Abstract][Full Text] [Related]
7. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.
Dahal K; Kunwar S; Rijal J; Schulman P; Lee J
Chest; 2016 Apr; 149(4):951-9. PubMed ID: 26378611
[TBL] [Abstract][Full Text] [Related]
8. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study.
Wakasugi M; Kazama JJ; Tokumoto A; Suzuki K; Kageyama S; Ohya K; Miura Y; Kawachi M; Takata T; Nagai M; Ohya M; Kutsuwada K; Okajima H; Ei I; Takahashi S; Narita I
Clin Exp Nephrol; 2014 Aug; 18(4):662-9. PubMed ID: 24113782
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
10. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.
Chan PH; Huang D; Yip PS; Hai J; Tse HF; Chan TM; Lip GY; Lo WK; Siu CW
Europace; 2016 May; 18(5):665-71. PubMed ID: 26504109
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies.
Liu G; Long M; Hu X; Hu CH; Liao XX; Du ZM; Dong YG
Medicine (Baltimore); 2015 Dec; 94(50):e2233. PubMed ID: 26683937
[TBL] [Abstract][Full Text] [Related]
13. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
14. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
15. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
19. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
20. A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials.
Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Valdés M; Vicente V; Roldán V; Lip GYH
Mayo Clin Proc; 2018 Aug; 93(8):1065-1073. PubMed ID: 29730090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
